AdvisorShares Trust → Neuphoria Therapeutics Inc. NEUP

Stake: — Shares: — Class: Common Stock, $0.00001 par value per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

5 transactions

5 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

5 filings by this filer

4 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 1.61

20,022 shares short · -19.0% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-01-20	Wilson David Ian	director	Award	8,537	—	—
2026-01-20	Davies Peter Miles Winston	director	Award	8,537	—	—
2026-01-20	Fisher Alan	director	Award	17,073	—	—
2026-01-20	Ryan Jane	director	Award	8,537	—	—
2025-10-21	Lynx1 Capital Management LP	10%+ owner	Buy	639,110	$5.14	$3.28M

Other 13D/G Filings on Neuphoria Therapeutics Inc.

Filed	Form	Filer	Stake	Shares
2025-12-29	SCHEDULE	Lynx1 Capital Management LP	16.30%	875,328	view →
2025-01-28	SCHEDULE	Apeiron Investment Group Ltd.	4.50%	72,618	view →
2024-10-07	SC	Apeiron Investment Group Ltd.	—	—	view →

Other Filings by AdvisorShares Trust

Filed	Form	Issuer	Stake	Shares
2026-10-05	SCHEDULE 13G	PSYENCE BIOMEDICAL LTD.	—	—	view →
2026-07-08	SCHEDULE 13G	Quantum Biopharma Ltd. QNTM	—	—	view →
2026-07-08	SCHEDULE 13G	Trulieve Cannabis Corp. TCNNF	—	—	view →
2026-07-08	SCHEDULE 13G	Silo Pharma, Inc. SILO	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →